Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics Starts US Phase I Trial of RNAi Anticoagulant

publication date: Apr 12, 2023

Suzhou’s Sirnaomics announced plans to start a US Phase I trial of its novel RNAi Factor XI anticoagulant. Factor XI (FXI) is an enzyme produced in the liver that plays an important role in the body's blood clotting cascade. Because FXI impacts the intrinsic coagulation pathway while leaving the extrinsic pathway and bleeding time intact, it is a prime target for anticoagulation needs in atrial fibrillation, pulmonary embolism, deep vein thrombosis, and deep venous thrombosis prophylaxis. It is the first siRNA-based candidate to target the major unmet need of anticoagulation disorders. More details....

Stock Symbol: (HK: 2257)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital